Drug General Information (ID: DDI4JQ3ESX)
Drug Name			Cladribine		Drug Info		Peginterferon beta-1a		Drug Info
Drug Type		Small molecule				Interferons
Therapeutic Class		Antineoplastics				Interferons

Mechanism of Cladribine-Peginterferon beta-1a Interaction (Severity Level: Moderate)
Additive myelosuppressive effects Click to Show/Hide Mechanism Graph
Drug Name		Cladribine				Peginterferon beta-1a
Mechanism		Myelosuppressive effects Risk of lymphopenia				Myelosuppressive effects Risk of lymphopenia
Key Mechanism Factor 1
		Factor Name		Myelosuppressive effects
		Factor Description		Myelosuppression, also known as bone marrow suppression, is a decrease in bone marrow activity that leads to a decrease in the production of blood cells. Some blood cell disorders include: erythrocytopenia (anemia), leukopenia (neutropenia), and thrombocytopenia (thrombocytopenia).
Mechanism Description		Additive myelosuppressive effects by the combination of Cladribine and Peginterferon beta-1a

Recommended Action
Management		Concomitant use of cladribine and beta interferons is not recommended.

References
1	Cerner Multum, Inc. "Australian Product Information.".
2	Product Information. Leustatin (cladribine). Ortho Biotech Inc, Raritan, NJ.
3	Montalban X, Leist TP, Cohen BA, et.al "Cladribine tablets added to IFN-a in active relapsing MS: The ONWARD study." Neurol Neruroimmunol Neuroinflamm 11 (2018): e477